References
- Gugler R, Herald W, Dengler H J. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974; 7: 17–24
- McDevitt D G, Shand D G. Plasma concentrations and the time-course of beta-blockade due to propranolol. Clin Pharmacol Ther. 1975; 18: 708–13
- Ishizaki T. Likely explanation for longer duration of pharmacological (antianginal) effects of propranolol in relation to its short half-life. Res Commun Chem Pathol Pharmacol. 1980; 27: 223–39
- Wellstein A, Palm D, Pitschner H F, Belz G G. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol. 1985; 29: 131–47
- Kurjak A, Alfirevic Z, Miljan M. Conventional and color Doppler in the assessment of fetal and maternal circulation. Ultrasound Med Biol. 1988; 14: 337–54
- Kaila T. A sensitive radioligand binding assay for timolol in plasma. J Pharm Sci. 1991; 80: 296–9
- Lubbe W F. Hypertension in pregnancy: Whom and how to treat. Br J Clin Pharmacol. 1987; 24(Suppl 1)158
- Fiddler G I. Propranolol and pregnancy. Lancet 1974; 2: 722–3
- Kjellmer I, Dagbjartsson A, Hrbek A, Karlsson K, Rosen K G. Maternal beta-adrenoreceptor blockade reduces fetal tolerance to asphyxia. Acta Obstet Gynecol Scand Suppl. 1984, Suppl 118: 75–80
- Butters L, Kennedy S, Rubin P C. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301: 587–9
- Dubois D, Petitcolas J, Temperville B, Klepper A. Treatment of hypertension in pregnancy with beta-adrenoreceptor antagonists. Br J Clin Pharmacol. 1982; 13: 375–8
- Sukerman-Voldman E. Pindolol therapy in pregnant hypertensive patients. Br J Clin Pharmacol. 1982; 13: 379
- Montan S, Ingemarsson I, Marsal K, Sjoberg N-O. Randomized controlled trial of atenolol and pindolol in human pregnancy: Effects on fetal haemodynamics. BMJ 1992; 304: 946–9
- Hanson L. Beta-adrenergic blockade in essential hypertension. Acta Med Scand Suppl. 1973, Suppl 550: 1
- Atterhög J H, Duner H, Pernow B. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976; 60: 872
- Lunell N O, Nylund L, Lewander R, Sarby B, Wager J. Uteroplacental blood flow in pregnancy hypertension after the administration of a beta-adrenoreceptor blocker, pindolol. Gynecol Obstet Invest. 1984; 18: 269–74
- Tuimala R, Hartikainen-Sorri A-L. Randomized comparison of atenolol and pindolol for treatment of hypertension in pregnancy. Curr Ther Res. 1988; 44: 579–84
- Ingemarsson I, Adaikan P G, Arulkumaran S, Kottegoda S R. Effect of a beta-adrenoreceptor antagonist, pindolol, on human uterine smooth muscle. Gynecol Obstet Invest. 1987; 24: 185–9
- Egarter C, Meisner W, Kroboth W K, Grunberger W. Effect of beta-adrenoreceptor blockers on uterine contractility in a puerperal model. Acta Obstet Gynecol Scand. 1989; 68: 359–62
- Juma F D. Pharmacokinetics of pindolol in Kenyan Africans. Eur J Clin Pharmacol. 1983; 25: 425–6
- Gretzer I, Alvan G, Duner H, Garle M, Sjöqvist F. Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients. Eur J Clin Pharmacol. 1986; 31: 415–9
- Aellig W H. Clinical pharmacology of pindolol. Am Heart J. 1982; 104: 346–56